SequelSEC

Gain Therapeutics, Inc. GANX

Pharmaceutical Preparations · CIK 0001819411 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$55.18K
Fiscal year ended 2023-12-31
Operating income
-$22.25M
Fiscal year ended 2023-12-31
Free cash flow
Unavailable
Fiscal year ended 2023-12-31

Gain Therapeutics, Inc. (GANX) reported revenue of $55.18K and net income of -$22.27M for the fiscal year ended 2023-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Gain Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Gain Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312022-12-312021-12-312020-12-31
Revenue$55.18K$140.11K$164.99K$28.88K
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$22.25M-$17.78M-$13.83M-$3.48M
Net income-$22.27M-$17.59M-$13.89M-$3.58M
Research & development$11.52M$8.38M$7.16M$2.26M
Weighted-average diluted sharesshares 13.01Mshares 11.88Mshares 10.17Mshares 2.68M
Pretax income-$22.19M-$17.50M-$13.89M-$3.57M
Income tax expense$79.28K$92.98K$4.01K$5.39K
Diluted EPS$-1.71$-1.48$-1.37$-1.33
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$10.79M$9.54M$6.83M$1.25M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

Gain Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$11.79M$7.31M$36.88M$7.49M
Total assets$18.61M$24.10M$38.99M$9.60M
Current assets$17.78M$21.09M$37.72M$8.99M
Total liabilities$6.03M$5.22M$4.17M$3.40M
Current liabilities$4.95M$4.13M$2.55M$2.11M
Total equity incl. NCI$12.58M$18.88M$34.82M$6.20M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable$8.55K
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debt$449.05K$495.26K$590.47K$715.66K
Accounts payable$1.32M$1.63M$560.48K$961.52K

Cash flow

Gain Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$18.87M-$14.69M-$12.37M-$3.24M
Capital expendituresUnavailableUnavailable$94.21K$20.83K
Investing cash flow$10.22M-$14.77M-$94.21K-$20.83K
Financing cash flow$12.64M-$78.77K$41.77M$10.49M
Net change in cash$4.49M-$29.57M$29.41M$7.19M
Stock-based compensation$3.26M$1.53M$839.37K$81.64K
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$83.58K$64.17K$15.48K$9.59K

Derived

Gain Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312022-12-312021-12-312020-12-31
Free cash flowUnavailableUnavailableUnavailable-$3.26M
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating margin-40328.3%-12688.1%-8379.8%-12047.5%
FCF marginUnavailableUnavailableUnavailable-11291.4%
SBC / revenue5906.2%1089.5%508.7%282.7%
Current ratio3.59x5.11x14.78x4.25x
Revenue YoY growth-60.6%-15.1%471.3%Unavailable
Net margin-40354.3%-12555.1%-8418.9%-12387.7%
R&D / revenue20878.2%5979.2%4342.1%7822.5%
CapEx / revenueUnavailableUnavailableUnavailable72.1%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open GANX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.